Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Jefferies Group cut their FY2017 EPS estimates for shares of Alnylam Pharmaceuticals in a report released on Wednesday. Jefferies Group analyst M. Raycroft now anticipates that the biopharmaceutical company will post earnings per share of ($5.49) for the year, down from their previous forecast of ($5.46). Jefferies Group has a “Buy” rating and a $130.00 price target on the stock. Jefferies Group also issued estimates for Alnylam Pharmaceuticals’ FY2018 earnings at ($5.40) EPS, FY2019 earnings at ($4.29) EPS, FY2020 earnings at ($2.10) EPS and FY2021 earnings at $0.84 EPS.

Several other brokerages have also weighed in on ALNY. Credit Suisse Group increased their price objective on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. B. Riley assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 price objective on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $56.00 price objective (up from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Cowen and Company reissued a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday. Finally, Chardan Capital reissued a “buy” rating and issued a $124.00 price objective (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $114.57.

WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-to-post-fy2017-earnings-of-5-49-per-share-jefferies-group-forecasts/1697200.html.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $139.98 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 8.84. Alnylam Pharmaceuticals has a 1 year low of $35.98 and a 1 year high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter in the previous year, the company posted ($1.21) EPS. The business’s revenue for the quarter was up 24.8% compared to the same quarter last year.

In other news, Director Dennis A. Ausiello sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total value of $2,600,000.00. Following the sale, the director now directly owns 20,000 shares in the company, valued at approximately $2,600,000. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The disclosure for this sale can be found here. Insiders have sold 215,797 shares of company stock worth $25,035,072 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 22.0% in the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 2,093 shares in the last quarter. California Public Employees Retirement System boosted its stake in shares of Alnylam Pharmaceuticals by 14.4% in the 2nd quarter. California Public Employees Retirement System now owns 126,700 shares of the biopharmaceutical company’s stock valued at $10,106,000 after purchasing an additional 15,900 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $1,060,000. Hemenway Trust Co LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $235,000. Finally, Federated Investors Inc. PA boosted its stake in shares of Alnylam Pharmaceuticals by 522.9% in the 2nd quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock valued at $4,968,000 after purchasing an additional 52,293 shares in the last quarter. Institutional investors own 94.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.